More articles about Diagnostics

Burning Rock also said it will continue to develop companion diagnostics-related products based on next-generation sequencing technology.

The test is based on the US Centers for Disease Control and Prevention's SARS-CoV-2 panel and detects two regions of the virus' nucleocapsid gene.

Both tests are authorized for use by any laboratory CLIA certified to perform high-complexity tests, according to the FDA.

The investment bank said CareDx's products are gaining traction and that the stock is positioned for 20 percent to 30 percent growth over the next few years.

For the three months ended March 31, the firm reported revenues of $9.2 million, up from $6.0 million in the year-ago quarter and beating the consensus Wall Street estimate of $8.9 million.

Both PCR-based tests are designed to detect SARS-CoV-2 nucleic acid in upper respiratory specimens and may only be performed by their developers.

Recent guidance from HHS has improved data collection by clarifying which testing data all laboratories must report, including demographic data.

The cancer molecular diagnostics firm said it will use the proceeds from the offering to support its R&D activities and for general corporate purposes.

Babson recently signed an agreement to provide SARS-CoV-2 serology testing services for a study being conducted at the University of Texas at Austin.